News

The suite includes a designated area for the small-scale development and manufacturing of solid dosage forms for customers’ early clinical study needs. The 2,500sqft suite is designed to

In the clinical study conducted in 16 healthy volunteers, SD-254 exhibited a pharmacokinetic profile that appears to be superior to that of venlafaxine and consistent with that required

The Phase II trial is a multicenter, double-blind, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist specific to

The financing was co-led by Quaker BioVentures and MedImmune Ventures. Other investors included Red Abbey Venture Partners, Maryland Health Care Product Development Corporation and Acidophil. The company said

As part of the agreement GlaxoSmithKline Biologicals (GSK) is acquiring exclusive rights to develop and commercialize two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology

IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin conjugated to a cyclodextrin polymer. IT-101, the first drug candidate in Calando’s proprietary Cyclosert pipeline, has

The latest analysis focused on a prospective group of patients (n=50) with an annualized relapse rate (ARR) of greater than one at study entry which is comparable to

This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. This data provide the scientific rationale for an ongoing

Most recently, Mr Arlotta has served as chairman, president and CEO of Coram, a provider of specialty infusion and pharmacy distribution services that was acquired by Apria Healthcare